{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T07:51:17Z","timestamp":1749801077946,"version":"3.32.0"},"reference-count":94,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Malaria has been one of the most lethal infectious diseases throughout history, claiming a\nhigh number of human lives. The genomic plasticity of &lt;i&gt;Plasmodium falciparum&lt;\/i&gt;, the causative agent\nof the most severe and deadly form of malaria, gives the parasite a constant resistance to drugs developed\nfor its control. Despite efforts to control and even eradicate the disease, these have largely\nbeen unsuccessful due to the parasite's continuous adaptations. This study aims to examine the key\ngenes involved in parasite resistance and propose a shift in the combat strategy. Gene silencing\ntechniques offer promise in combating malaria, yet further research is needed to harness their potential\nfor disease control fully. Although there is still a long way to go for the implementation of gene\nsilencing-based therapeutic strategies, this review addresses examples of the use of such techniques\nin various human diseases and how they could be extrapolated for malaria treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113895575306957240610102626","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T07:04:03Z","timestamp":1719212643000},"page":"128-137","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring Genetic Silencing: RNAi and CRISPR-Cas Potential against Drug Resistance in Malaria"],"prefix":"10.2174","volume":"25","author":[{"given":"Carlos","family":"Gaona-Lopez","sequence":"first","affiliation":[{"name":"Laboratorio de Biotecnologia Farmaceutica, Centro de Biotecnologia Genomica, Instituto Politecnico Nacional, Reynosa, 88710, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9842-4167","authenticated-orcid":true,"given":"Gildardo","family":"Rivera","sequence":"additional","affiliation":[{"name":"Laboratorio de Biotecnologia Farmaceutica, Centro de Biotecnologia Genomica, Instituto Politecnico Nacional,\nReynosa, 88710, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1756-3305-3-5","volume":"3","author":"Cox F.E.G.","year":"2010","unstructured":"Cox F.E.G.; History of the discovery of the malaria parasites and their vectors. Parasit Vectors  2010,3(1),5","journal-title":"Parasit Vectors"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1126\/science.1081449","volume":"300","author":"Joy D.A.","year":"2003","unstructured":"Joy D.A.; Feng X.; Mu J.; Furuya T.; Chotivanich K.; Krettli A.U.; Ho M.; Wang A.; White N.J.; Suh E.; Beerli P.; Su X.; Early origin and recent expansion of Plasmodium falciparum. Science  2003,300(5617),318-321","journal-title":"Science"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nature19365","volume":"538","author":"Timmermann A.","year":"2016","unstructured":"Timmermann A.; Friedrich T.; Late Pleistocene climate drivers of early human migration. Nature  2016,538(7623),92-95","journal-title":"Nature"},{"year":"2021","key":"ref=4","unstructured":"Global Malaria Programme. World malaria report 2021. World Health Organization Available From:  https:\/\/www.who.int\/teams\/global-malariaprogramme\/reports\/world-malaria-report-20212021"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"a025569","DOI":"10.1101\/cshperspect.a025569","volume":"8","author":"Milner D.A.","year":"2018","unstructured":"Milner D.A.; Malaria pathogenesis. Cold Spring Harb Perspect Med  2018,8(1),a025569","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=6","unstructured":"The top 10 causes of death. World Health Organization Available From:  https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1756-3305-5-69","volume":"5","author":"Sinka M.E.","year":"2012","unstructured":"Sinka M.E.; Bangs M.J.; Manguin S.; Rubio-Palis Y.; Chareonviriyaphap T.; Coetzee M.; Mbogo C.M.; Hemingway J.; Patil A.P.; Temperley W.H.; Gething P.W.; Kabaria C.W.; Burkot T.R.; Harbach R.E.; Hay S.I.; A global map of dominant malaria vectors. Parasit Vectors  2012,5(1),69","journal-title":"Parasit Vectors"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1146\/annurev-genet-120215-035211","volume":"50","author":"Molina-Cruz A.","year":"2016","unstructured":"Molina-Cruz A.; Zilversmit M.M.; Neafsey D.E.; Hartl D.L.; Barillas-Mury C.; Mosquito vectors and the globalization of Plasmodium falciparum malaria. Annu Rev Genet  2016,50(1),447-465","journal-title":"Annu Rev Genet"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1590\/s1678-9946202062100","volume":"62","author":"Aschar M.","year":"2020","unstructured":"Aschar M.; Levi J.E.; Farinas M.L.R.N.; Montebello S.C.; Mendrone-Junior A.; Di Santi S.M.; The hidden Plasmodium malariae in blood donors: A risk coming from areas of low transmission of malaria. Rev Inst Med Trop S&#xE3;o Paulo  2020,62,e100","journal-title":"Rev Inst Med Trop S&#xE3;o Paulo"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.32641\/rchped.v91i5.1283","volume":"91","author":"Del Castillo Calder&#xF3;n J.G.","year":"2020","unstructured":"Del Castillo Calder&#xF3;n J.G.; C&#xE1;rdenas Silva A.M.; Malaria cong&#xE9;nita por Plasmodium falciparum. Rev Chil Pediatr  2020,91(5),749-753","journal-title":"Rev Chil Pediatr"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"a025452","DOI":"10.1101\/cshperspect.a025452","volume":"7","author":"Meibalan E.","year":"2017","unstructured":"Meibalan E.; Marti M.; Biology of Malaria Transmission. Cold Spring Harb Perspect Med  2017,7(3),a025452","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0006-2952(97)00510-8","volume":"55","author":"Dorn A.","year":"1998","unstructured":"Dorn A.; Vippagunta S.R.; Matile H.; Jaquet C.; Vennerstrom J.L.; Ridley R.G.; An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials. Biochem Pharmacol  1998,55(6),727-736","journal-title":"Biochem Pharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1021\/cb300454t","volume":"8","author":"Combrinck J.M.","year":"2013","unstructured":"Combrinck J.M.; Mabotha T.E.; Ncokazi K.K.; Ambele M.A.; Taylor D.; Smith P.J.; Hoppe H.C.; Egan T.J.; Insights into the role of heme in the mechanism of action of antimalarials. ACS Chem Biol  2013,8(1),133-137","journal-title":"ACS Chem Biol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2174\/1566524020666200207123253","volume":"20","author":"Tang Y.Q.","year":"2020","unstructured":"Tang Y.Q.; Ye Q.; Huang H.; Zheng W.Y.; An overview of available antimalarials: Discovery, mode of action and drug resistance. Curr Mol Med  2020,20(8),583-592","journal-title":"Curr Mol Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.4269\/ajtmh.2006.75.402","volume":"75","author":"Hill D.R.","year":"2006","unstructured":"Hill D.R.; Ryan E.T.; Parise M.; Magill A.J.; Lewis L.S.; Baird J.K.; Primaquine: Report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg  2006,75(3),402-415","journal-title":"Am J Trop Med Hyg"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12936-019-2825-8","volume":"18","author":"Bonilla-Ram&#xED;rez L.","year":"2019","unstructured":"Bonilla-Ram&#xED;rez L.; Galiano S.; Quiliano M.; Aldana I.; Pab&#xF3;n A.; Primaquine\u2013quinoxaline 1,4-di-N-oxide hybrids with action on the exo-erythrocytic forms of Plasmodium induce their effect by the production of reactive oxygen species. Malar J  2019,18(1),201","journal-title":"Malar J"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.freeradbiomed.2021.03.001","volume":"167","author":"Egwu C.O.","year":"2021","unstructured":"Egwu C.O.; Tsamesidis I.; P&#xE9;rio P.; Augereau J.M.; Benoit-Vical F.; Reybier K.; Superoxide: A major role in the mechanism of action of essential antimalarial drugs. Free Radic Biol Med  2021,167,271-275","journal-title":"Free Radic Biol Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"e01416","DOI":"10.1128\/AAC.01416-20","volume":"65","author":"Demb&#xE9;l&#xE9; L.","year":"2020","unstructured":"Demb&#xE9;l&#xE9; L.; Franetich J.F.; Soulard V.; Amanzougaghene N.; Tajeri S.; Bousema T.; van Gemert G.J.; Le Grand R.; Dereuddre-Bosquet N.; Baird J.K.; Mazier D.; Snounou G.; Chloroquine potentiates primaquine activity against active and latent hepatic plasmodia ex vivo: Potentials and pitfalls. Antimicrob Agents Chemother  2020,65(1),e01416-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.chom.2019.06.001","volume":"26","author":"Ross L.S.","year":"2019","unstructured":"Ross L.S.; Fidock D.A.; Elucidating mechanisms of drug-resistant Plasmodium falciparum. Cell Host Microbe  2019,26(1),35-47","journal-title":"Cell Host Microbe"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"17031","DOI":"10.1038\/nmicrobiol.2017.31","volume":"2","author":"Wong W.","year":"2017","unstructured":"Wong W.; Bai X.C.; Sleebs B.E.; Triglia T.; Brown A.; Thompson J.K.; Jackson K.E.; Hanssen E.; Marapana D.S.; Fernandez I.S.; Ralph S.A.; Cowman A.F.; Scheres S.H.W.; Baum J.; Mefloquine targets the Plasmodium falciparum 80s ribosome to inhibit protein synthesis. Nat Microbiol  2017,2(6),17031","journal-title":"Nat Microbiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ijpddr.2020.10.009","volume":"14","author":"Windle S.T.","year":"2020","unstructured":"Windle S.T.; Lane K.D.; Gadalla N.B.; Liu A.; Mu J.; Caleon R.L.; Rahman R.S.; S&#xE1; J.M.; Wellems T.E.; Evidence for linkage of pfmdr1, pfcrt, and pfk13 polymorphisms to lumefantrine and mefloquine susceptibilities in a Plasmodium falciparum cross. Int J Parasitol Drugs Drug Resist  2020,14,208-217","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"821","DOI":"10.4269\/ajtmh.2005.73.821","volume":"73","author":"Meshnick S.R.","year":"2005","unstructured":"Meshnick S.R.; Alker A.P.; Amodiaquine and combination chemotherapy for malaria. Am J Trop Med Hyg  2005,73(5),821-823","journal-title":"Am J Trop Med Hyg"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"CD004529","DOI":"10.1002\/14651858.CD004529.pub2","volume":"2005","author":"Osei-Akoto A.","year":"2005","unstructured":"Osei-Akoto A.; Orton L.C.; Owusu-Ofori S.; Atovaquone-proguanil for treating uncomplicated malaria. Cochrane Libr  2005,2005(4),CD004529","journal-title":"Cochrane Libr"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.bbrc.2020.12.004","volume":"534","author":"Mounkoro P.","year":"2021","unstructured":"Mounkoro P.; Michel T.; Meunier B.; Revisiting the mode of action of the antimalarial proguanil using the yeast model. Biochem Biophys Res Commun  2021,534,94-98","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0163-7258(00)00115-7","volume":"89","author":"Olliaro P.","year":"2001","unstructured":"Olliaro P.; Mode of action and mechanisms of resistance for antimalarial drugs. Pharmacol Ther  2001,89(2),207-219","journal-title":"Pharmacol Ther"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1128\/AAC.00527-07","volume":"51","author":"Dahl E.L.","year":"2007","unstructured":"Dahl E.L.; Rosenthal P.J.; Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob Agents Chemother  2007,51(10),3485-3490","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1101\/gr.105163.110","volume":"20","author":"Dharia N.V.","year":"2010","unstructured":"Dharia N.V.; Plouffe D.; Bopp S.E.R.; Gonz&#xE1;lez-P&#xE1;ez G.E.; Lucas C.; Salas C.; Soberon V.; Bursulaya B.; Kochel T.J.; Bacon D.J.; Winzeler E.A.; Genome scanning of Amazonian Plasmodium falciparum shows subtelomeric instability and clindamycin-resistant parasites. Genome Res  2010,20(11),1534-1544","journal-title":"Genome Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0020-7519(02)00194-7","volume":"32","author":"Meshnick S.R.","year":"2002","unstructured":"Meshnick S.R.; Artemisinin: Mechanisms of action, resistance and toxicity. Int J Parasitol  2002,32(13),1655-1660","journal-title":"Int J Parasitol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1002\/med.21849","volume":"41","author":"Woodley C.M.","year":"2021","unstructured":"Woodley C.M.; Amado P.S.M.; Cristiano M.L.S.; O\u2019Neill P.M.; Artemisinin inspired synthetic endoperoxide drug candidates: Design, synthesis, and mechanism of action studies. Med Res Rev  2021,41(6),3062-3095","journal-title":"Med Res Rev"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/bcp.14474","volume":"88","author":"Hanboonkunupakarn B.","year":"2022","unstructured":"Hanboonkunupakarn B.; White N.J.; Advances and roadblocks in the treatment of malaria. Br J Clin Pharmacol  2022,88(2),374-382","journal-title":"Br J Clin Pharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1051\/parasite\/2014059","volume":"21","author":"Sinha S.","year":"2014","unstructured":"Sinha S.; Medhi B.; Sehgal R.; Challenges of drug-resistant malaria. Parasite  2014,21,61","journal-title":"Parasite"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12936-022-04115-8","volume":"21","author":"Plowe C.V.","year":"2022","unstructured":"Plowe C.V.; Malaria chemoprevention and drug resistance: A review of the literature and policy implications. Malar J  2022,21(1),104","journal-title":"Malar J"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/5539544","volume":"2021","author":"Amelo W.","year":"2021","unstructured":"Amelo W.; Makonnen E.; Efforts made to eliminate drug-resistant malaria and its challenges. BioMed Res Int  2021,2021,1-12","journal-title":"BioMed Res Int"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1038\/d41586-023-02052-3","volume":"618","author":"Padma T.V.","year":"2023","unstructured":"Padma T.V.; Can malaria researchers slow the spread of drug resistance? Nature  2023,618(7967),S26-S28","journal-title":"Nature"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.ijpara.2004.10.013","volume":"34","author":"Kumar N.","year":"2004","unstructured":"Kumar N.; Cha G.; Pineda F.; Maciel J.; Haddad D.; Bhattacharyya M.; Nagayasu E.; Molecular complexity of sexual development and gene regulation in Plasmodium falciparum. Int J Parasitol  2004,34(13-14),1451-1458","journal-title":"Int J Parasitol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"8502","DOI":"10.1073\/pnas.1232502100","volume":"100","author":"Feng X.","year":"2003","unstructured":"Feng X.; Carlton J.M.; Joy D.A.; Mu J.; Furuya T.; Suh B.B.; Wang Y.; Barnwell J.W.; Su X.Z.; Single-nucleotide polymorphisms and genome diversity in Plasmodium vivax. Proc Natl Acad Sci USA  2003,100(14),8502-8507","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/mmi.14632","volume":"115","author":"Zhang X.","year":"2021","unstructured":"Zhang X.; Deitsch K.W.; Kirkman L.A.; The contribution of extrachromosomal DNA to genome plasticity in malaria parasites. Mol Microbiol  2021,115(4),503-507","journal-title":"Mol Microbiol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12936-017-1806-z","volume":"16","author":"Costa G.L.","year":"2017","unstructured":"Costa G.L.; Amaral L.C.; Fontes C.J.F.; Carvalho L.H.; de Brito C.F.A.; de Sousa T.N.; Assessment of copy number variation in genes related to drug resistance in Plasmodium vivax and Plasmodium falciparum isolates from the Brazilian Amazon and a systematic review of the literature. Malar J  2017,16(1),152","journal-title":"Malar J"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/trstmh\/trz059","volume":"113","author":"Bakhiet A.M.A.","year":"2019","unstructured":"Bakhiet A.M.A.; Abdelraheem M.H.; Kheir A.; Omer S.; Gismelseed L.; Abdel-Muhsin A.M.A.; Naiem A.; Al Hosni A.; Al Dhuhli A.; Al Rubkhi M.; Al-Hamidhi S.; Gadalla A.; Mukhtar M.; Sultan A.A.; Babiker H.A.; Evolution of Plasmodium falciparum drug resistance genes following artemisinin combination therapy in Sudan. Trans R Soc Trop Med Hyg  2019,113(11),693-700","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0140-6736(04)16767-6","volume":"364","author":"Price R.N.","year":"2004","unstructured":"Price R.N.; Uhlemann A.C.; Brockman A.; McGready R.; Ashley E.; Phaipun L.; Patel R.; Laing K.; Looareesuwan S.; White N.J.; Nosten F.; Krishna S.; Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet  2004,364(9432),438-447","journal-title":"Lancet"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1475-2875-8-11","volume":"8","author":"Lim P.","year":"2009","unstructured":"Lim P.; Alker A.P.; Khim N.; Shah N.K.; Incardona S.; Doung S.; Yi P.; Bouth D.M.; Bouchier C.; Puijalon O.M.; Meshnick S.R.; Wongsrichanalai C.; Fandeur T.; Le Bras J.; Ringwald P.; Ariey F.; Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar J  2009,8(1),11","journal-title":"Malar J"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1179\/2047773214Y.0000000158","volume":"108","author":"Li J.","year":"2014","unstructured":"Li J.; Chen J.; Xie D.; Monte-Nguba S.; Eyi J.U.M.; Matesa R.A.; Obono M.M.O.; Ehapo C.S.; Yang L.; Lu D.; Yang H.; Yang H.T.; Lin M.; High prevalence of pfmdr1 N86Y and Y184F mutations in Plasmodium falciparum isolates from Bioko island, Equatorial Guinea. Pathog Glob Health  2014,108(7),339-343","journal-title":"Pathog Glob Health"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.meegid.2011.01.003","volume":"11","author":"Lekana-Douki J.B.","year":"2011","unstructured":"Lekana-Douki J.B.; Boutamba S.D.D.; Zatra R.; Edou S.E.Z.; Ekomy H.; Bisvigou U.; Toure-Ndouo F.S.; Increased prevalence of the Plasmodium falciparum Pfmdr1 86N genotype among field isolates from Franceville, Gabon after replacement of chloroquine by artemether\u2013lumefantrine and artesunate\u2013mefloquine. Infect Genet Evol  2011,11(2),512-517","journal-title":"Infect Genet Evol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ijpara.2020.10.001","volume":"51","author":"Kayode A.T.","year":"2021","unstructured":"Kayode A.T.; Akano K.; Ajogbasile F.V.; Uwanibe J.N.; Oluniyi P.E.; Bankole B.E.; Eromon P.J.; Sowunmi A.; Folarin O.A.; Volkman S.K.; McInnis B.; Sabeti P.; Wirth D.F.; Happi C.T.; Polymorphisms in Plasmodium falciparum chloroquine resistance transporter (Pfcrt) and multidrug-resistant gene 1 (Pfmdr-1) in Nigerian children 10 years post-adoption of artemisinin-based combination treatments. Int J Parasitol  2021,51(4),301-310","journal-title":"Int J Parasitol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev-micro-020518-115546","volume":"74","author":"Wicht K.J.","year":"2020","unstructured":"Wicht K.J.; Mok S.; Fidock D.A.; Molecular mechanisms of drug resistance in Plasmodium falciparum malaria. Annu Rev Microbiol  2020,74(1),431-454","journal-title":"Annu Rev Microbiol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S1097-2765(05)00077-8","volume":"6","author":"Fidock D.A.","year":"2000","unstructured":"Fidock D.A.; Nomura T.; Talley A.K.; Cooper R.A.; Dzekunov S.M.; Ferdig M.T.; Ursos L.M.B.; bir Singh Sidhu, A.; Naud&#xE9;, B.; Deitsch, K.W.; Su, X.; Wootton, J.C.; Roepe, P.D.; Wellems, T.E. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell  2000,6(4),861-871","journal-title":"Mol Cell"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"e00303","DOI":"10.1128\/mBio.00303-17","volume":"8","author":"Dhingra S.K.","year":"2017","unstructured":"Dhingra S.K.; Redhi D.; Combrinck J.M.; Yeo T.; Okombo J.; Henrich P.P.; Cowell A.N.; Gupta P.; Stegman M.L.; Hoke J.M.; Cooper R.A.; Winzeler E.; Mok S.; Egan T.J.; Fidock D.A.; A variant PfCRT isoform can contribute to Plasmodium falciparum resistance to the first-line partner drug piperaquine. MBio  2017,8(3),e00303-17","journal-title":"MBio"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2217\/17460913.1.1.113","volume":"1","author":"Yuthavong Y.","year":"2006","unstructured":"Yuthavong Y.; Kamchonwongpaisan S.; Leartsakulpanich U.; Chitnumsub P.; Folate metabolism as a source of molecular targets for antimalarials. Future Microbiol  2006,1(1),113-125","journal-title":"Future Microbiol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"769","DOI":"10.4155\/fmc.13.43","volume":"5","author":"Kronenberger T.","year":"2013","unstructured":"Kronenberger T.; Schettert I.; Wrenger C.; Targeting the vitamin biosynthesis pathways for the treatment of malaria. Future Med Chem  2013,5(7),769-779","journal-title":"Future Med Chem"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"e01538","DOI":"10.1128\/aac.01538-21","volume":"66","author":"Pethrak C.","year":"2022","unstructured":"Pethrak C.; Posayapisit N.; Pengon J.; Suwanakitti N.; Saeung A.; Shorum M.; Aupalee K.; Taai K.; Yuthavong Y.; Kamchonwongpaisan S.; Jupatanakul N.; New insights into antimalarial chemopreventive activity of antifolates. Antimicrob Agents Chemother  2022,66(2),e01538-21","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12936-019-2734-x","volume":"18","author":"Jiang T.","year":"2019","unstructured":"Jiang T.; Chen J.; Fu H.; Wu K.; Yao Y.; Eyi J.U.M.; Matesa R.A.; Obono M.M.O.; Du W.; Tan H.; Lin M.; Li J.; High prevalence of pfdhfr\u2013pfdhps quadruple mutations associated with sulfadoxine\u2013pyrimethamine resistance in Plasmodium falciparum isolates from Bioko Island, Equatorial Guinea. Malar J  2019,18(1),101","journal-title":"Malar J"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"673194","DOI":"10.3389\/fcimb.2021.673194","volume":"11","author":"Yan H.","year":"2021","unstructured":"Yan H.; Feng J.; Yin J.; Huang F.; Kong X.; Lin K.; Zhang T.; Feng X.; Zhou S.; Cao J.; Xia Z.; High frequency mutations in pfdhfr and pfdhps of plasmodium falciparum in response to sulfadoxine-pyrimethamine: A cross-sectional survey in returning Chinese migrants from Africa. Front Cell Infect Microbiol  2021,11,673194","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00436-018-5754-5","volume":"117","author":"Esu E.","year":"2018","unstructured":"Esu E.; Tacoli C.; Gai P.; Berens-Riha N.; Pritsch M.; Loescher T.; Meremikwu M.; Prevalence of the Pfdhfr and Pfdhps mutations among asymptomatic pregnant women in Southeast Nigeria. Parasitol Res  2018,117(3),801-807","journal-title":"Parasitol Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1186\/s12936-020-03524-x","volume":"19","author":"Madkhali A.M.","year":"2020","unstructured":"Madkhali A.M.; Al-Mekhlafi H.M.; Atroosh W.M.; Ghzwani A.H.; Zain K.A.; Abdulhaq A.A.; Ghailan K.Y.; Anwar A.A.; Eisa Z.M.; Increased prevalence of pfdhfr and pfdhps mutations associated with sulfadoxine\u2013pyrimethamine resistance in Plasmodium falciparum isolates from Jazan Region, Southwestern Saudi Arabia: Important implications for malaria treatment policy. Malar J  2020,19(1),446","journal-title":"Malar J"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"e0278928","DOI":"10.1371\/journal.pone.0278928","volume":"17","author":"Srisutham S.","year":"2022","unstructured":"Srisutham S.; Madmanee W.; Kouhathong J.; Sutawong K.; Tripura R.; Peto T.J.; van der Pluijm R.W.; Callery J.J.; Dysoley L.; Mayxay M.; Newton P.N.; Pongvongsa T.; Hongvanthong B.; Day N.P.J.; White N.J.; Dondorp A.M.; Imwong M.; Ten-year persistence and evolution of Plasmodium falciparum antifolate and anti-sulfonamide resistance markers pfdhfr and pfdhps in three Asian countries. PLoS One  2022,17(12),e0278928","journal-title":"PLoS One"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/jcp.1041540311","volume":"154","author":"Bosia A.","year":"1993","unstructured":"Bosia A.; Ghigo D.; Turrini F.; Nissani E.; Pescarmona G.P.; Ginsburg H.; Kinetic characterization of Na +\/H + antiport of Plasmodium falciparum membrane. J Cell Physiol  1993,154(3),527-534","journal-title":"J Cell Physiol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1128\/AAC.01243-08","volume":"53","author":"Henry M.","year":"2009","unstructured":"Henry M.; Briolant S.; Zettor A.; Pelleau S.; Baragatti M.; Baret E.; Mosnier J.; Amalvict R.; Fusai T.; Rogier C.; Pradines B.; Plasmodium falciparum Na+\/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine. Antimicrob Agents Chemother  2009,53(5),1926-1930","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1128\/AAC.02472-14","volume":"58","author":"Cheruiyot J.","year":"2014","unstructured":"Cheruiyot J.; Ingasia L.A.; Omondi A.A.; Juma D.W.; Opot B.H.; Ndegwa J.M.; Mativo J.; Cheruiyot A.C.; Yeda R.; Okudo C.; Muiruri P.; Bidii N.S.; Chebon L.J.; Angienda P.O.; Eyase F.L.; Johnson J.D.; Bulimo W.D.; Andagalu B.; Akala H.M.; Kamau E.; Polymorphisms in Pfmdr1, Pfcrt, and Pfnhe1 genes are associated with reduced in vitro activities of quinine in Plasmodium falciparum isolates from western Kenya. Antimicrob Agents Chemother  2014,58(7),3737-3743","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s12879-019-3921-7","volume":"19","author":"Wu K.","year":"2019","unstructured":"Wu K.; Yao Y.; Chen F.; Xu M.; Lu G.; Jiang T.; Liu Z.; Du W.; Li F.; Li R.; Tan H.; Li J.; Analysis of Plasmodium falciparum Na+\/H+ exchanger (pfnhe1) polymorphisms among imported African malaria parasites isolated in Wuhan, Central China. BMC Infect Dis  2019,19(1),354","journal-title":"BMC Infect Dis"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"7329","DOI":"10.1080\/07391102.2022.2120539","volume":"41","author":"Sharma S.","year":"2023","unstructured":"Sharma S.; Ali M.E.; How do the mutations in Pf K13 protein promote anti-malarial drug resistance? J Biomol Struct Dyn  2023,41(15),7329-7338","journal-title":"J Biomol Struct Dyn"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s13071-023-06024-4","volume":"16","author":"Si W.","year":"2023","unstructured":"Si W.; Zhao Y.; Qin X.; Huang Y.; Yu J.; Liu X.; Li Y.; Yan X.; Zhang Q.; Sun J.; What exactly does the PfK13 C580Y mutation in Plasmodium falciparum influence? Parasit Vectors  2023,16(1),421","journal-title":"Parasit Vectors"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1126\/science.aax4735","volume":"367","author":"Birnbaum J.","year":"2020","unstructured":"Birnbaum J.; Scharf S.; Schmidt S.; Jonscher E.; Hoeijmakers W.A.M.; Flemming S.; Toenhake C.G.; Schmitt M.; Sabitzki R.; Bergmann B.; Fr&#xF6;hlke U.; Mes&#xE9;n-Ram&#xED;rez P.; Blancke Soares A.; Herrmann H.; B&#xE1;rtfai R.; Spielmann T.A.; Kelch13-defined endocytosis pathway mediates artemisinin resistance in malaria parasites. Science  2020,367(6473),51-59","journal-title":"Science"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-018-06221-1","volume":"9","author":"Bridgford J.L.","year":"2018","unstructured":"Bridgford J.L.; Xie S.C.; Cobbold S.A.; Pasaje C.F.A.; Herrmann S.; Yang T.; Gillett D.L.; Dick L.R.; Ralph S.A.; Dogovski C.; Spillman N.J.; Tilley L.; Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome. Nat Commun  2018,9(1),3801","journal-title":"Nat Commun"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.dnarep.2019.02.011","volume":"76","author":"Le J.","year":"2019","unstructured":"Le J.; Perez E.; Nemzow L.; Gong F.; Role of deubiquitinases in DNA damage response. DNA Repair  2019,76,89-98","journal-title":"DNA Repair"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"e02717","DOI":"10.1128\/AAC.02717-20","volume":"65","author":"Feng J.","year":"2021","unstructured":"Feng J.; Xu D.; Kong X.; Lin K.; Yan H.; Feng X.; Tu H.; Xia Z.; Characterization of pfmdr1, pfcrt, pfK13, pfubp1, and pfap2mu in Travelers Returning from Africa with Plasmodium falciparum Infections Reported in China from 2014 to 2018. Antimicrob Agents Chemother  2021,65(7),e02717-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"105286","DOI":"10.1016\/j.meegid.2022.105286","volume":"101","author":"Cheng W.","year":"2022","unstructured":"Cheng W.; Wu K.; Song X.; Wang W.; Du W.; Li J.; Single-nucleotide polymorphisms of artemisinin resistance-related pfubp1 and pfap2mu genes in imported Plasmodium falciparum to Wuhan, China. Infect Genet Evol  2022,101,105286","journal-title":"Infect Genet Evol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/ng.528","volume":"42","author":"Mu J.","year":"2010","unstructured":"Mu J.; Myers R.A.; Jiang H.; Liu S.; Ricklefs S.; Waisberg M.; Chotivanich K.; Wilairatana P.; Krudsood S.; White N.J.; Udomsangpetch R.; Cui L.; Ho M.; Ou F.; Li H.; Song J.; Li G.; Wang X.; Seila S.; Sokunthea S.; Socheat D.; Sturdevant D.E.; Porcella S.F.; Fairhurst R.M.; Wellems T.E.; Awadalla P.; Su X.; Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nat Genet  2010,42(3),268-271","journal-title":"Nat Genet"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3389\/fgene.2019.01065","volume":"10","author":"Ye R.","year":"2019","unstructured":"Ye R.; Tian Y.; Huang Y.; Zhang Y.; Wang J.; Sun X.; Zhou H.; Zhang D.; Pan W.; Genome-wide analysis of genetic diversity in Plasmodium falciparum isolates from China\u2013Myanmar border. Front Genet  2019,10,1065","journal-title":"Front Genet"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"e01542","DOI":"10.1128\/AAC.01542-19","volume":"64","author":"Henrici R.C.","year":"2019","unstructured":"Henrici R.C.; van Schalkwyk D.A.; Sutherland C.J.; Modification of pfap2&#x3BC; and pfubp1 Markedly Reduces Ring-Stage Susceptibility of Plasmodium falciparum to Artemisinin In Vitro. Antimicrob Agents Chemother  2019,64(1),e01542-19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.cell.2005.08.044","volume":"123","author":"Matranga C.","year":"2005","unstructured":"Matranga C.; Tomari Y.; Shin C.; Bartel D.P.; Zamore P.D.; Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell  2005,123(4),607-620","journal-title":"Cell"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"Setten R.L.","year":"2019","unstructured":"Setten R.L.; Rossi J.J.; Han S.; The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov  2019,18(6),421-446","journal-title":"Nat Rev Drug Discov"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/bab.2028","volume":"68","author":"Gheibi-Hayat S.M.","year":"2021","unstructured":"Gheibi-Hayat S.M.; Jamialahmadi K.; Antisense oligonucleotide (AS\u2010ODN) technology: Principle, mechanism and challenges. Biotechnol Appl Biochem  2021,68(5),1086-1094","journal-title":"Biotechnol Appl Biochem"},{"key":"ref=73","first-page":"187","volume":"85","author":"Gavrilov K.","year":"2012","unstructured":"Gavrilov K.; Saltzman W.M.; Therapeutic siRNA: Principles, challenges, and strategies. Yale J Biol Med  2012,85(2),187-200","journal-title":"Yale J Biol Med"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","volume":"27","author":"Kowalski P.S.","year":"2019","unstructured":"Kowalski P.S.; Rudra A.; Miao L.; Anderson D.G.; Delivering the messenger: Advances in technologies for therapeutic mRNA delivery. Mol Ther  2019,27(4),710-728","journal-title":"Mol Ther"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"Adams D.","year":"2018","unstructured":"Adams D.; Gonzalez-Duarte A.; O\u2019Riordan W.D.; Yang C.C.; Ueda M.; Kristen A.V.; Tournev I.; Schmidt H.H.; Coelho T.; Berk J.L.; Lin K.P.; Vita G.; Attarian S.; Plant&#xE9;-Bordeneuve V.; Mezei M.M.; Campistol J.M.; Buades J.; Brannagan T.H.; Kim B.J.; Oh J.; Parman Y.; Sekijima Y.; Hawkins P.N.; Solomon S.D.; Polydefkis M.; Dyck P.J.; Gandhi P.J.; Goyal S.; Chen J.; Strahs A.L.; Nochur S.V.; Sweetser M.T.; Garg P.P.; Vaishnaw A.K.; Gollob J.A.; Suhr O.B.; Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med  2018,379(1),11-21","journal-title":"N Engl J Med"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"592644","DOI":"10.3389\/fnmol.2020.592644","volume":"13","author":"Bezerra F.","year":"2020","unstructured":"Bezerra F.; Saraiva M.J.; Almeida M.R.; Modulation of the mechanisms driving transthyretin amyloidosis. Front Mol Neurosci  2020,13,592644","journal-title":"Front Mol Neurosci"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.3390\/ijms22094429","volume":"22","author":"Si J.B.","year":"2021","unstructured":"Si J.B.; Kim B.; Kim J.H.; Transthyretin misfolding, a fatal structural pathogenesis mechanism. Int J Mol Sci  2021,22(9),4429","journal-title":"Int J Mol Sci"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"105313","DOI":"10.1016\/j.neuint.2022.105313","volume":"155","author":"Ueda M.","year":"2022","unstructured":"Ueda M.; Transthyretin: Its function and amyloid formation. Neurochem Int  2022,155,105313","journal-title":"Neurochem Int"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/TCRM.S219979","volume":"16","author":"Luigetti M.","year":"2020","unstructured":"Luigetti M.; Romano A.; Di Paolantonio A.; Bisogni G.; Sabatelli M.; Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: Current perspectives on improving patient care. Ther Clin Risk Manag  2020,16,109-123","journal-title":"Ther Clin Risk Manag"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0166-6851(01)00429-7","volume":"119","author":"McRobert L.","year":"2002","unstructured":"McRobert L.; McConkey G.A.; RNA interference (RNAi) inhibits growth of Plasmodium falciparum. Mol Biochem Parasitol  2002,119(2),273-278","journal-title":"Mol Biochem Parasitol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"gkz927","DOI":"10.1093\/nar\/gkz927","author":"Hentzschel F.","year":"2019","unstructured":"Hentzschel F.; Mitesser V.; Fraschka S.A.K.; Krzikalla D.; Carrillo E.H.; Berkhout B.; B&#xE1;rtfai R.; Mueller A.K.; Grimm D.; Gene knockdown in malaria parasites via non-canonical RNAi. Nucleic Acids Res  2019,gkz927","journal-title":"Nucleic Acids Res"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1093\/nar\/gkp239","volume":"37","author":"Baum J.","year":"2009","unstructured":"Baum J.; Papenfuss A.T.; Mair G.R.; Janse C.J.; Vlachou D.; Waters A.P.; Cowman A.F.; Crabb B.S.; de Koning-Ward T.F.; Molecular genetics and comparative genomics reveal RNAi is not functional in malaria parasites. Nucleic Acids Res  2009,37(11),3788-3798","journal-title":"Nucleic Acids Res"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","volume":"384","author":"Garrelfs S.F.","year":"2021","unstructured":"Garrelfs S.F.; Frishberg Y.; Hulton S.A.; Koren M.J.; O\u2019Riordan W.D.; Cochat P.; Desch&#xEA;nes G.; Shasha-Lavsky H.; Saland J.M.; van\u2019t Hoff W.G.; Fuster D.G.; Magen D.; Moochhala S.H.; Schalk G.; Simkova E.; Groothoff J.W.; Sas D.J.; Meliambro K.A.; Lu J.; Sweetser M.T.; Garg P.P.; Vaishnaw A.K.; Gansner J.M.; McGregor T.L.; Lieske J.C.; Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med  2021,384(13),1216-1226","journal-title":"N Engl J Med"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","volume":"19","author":"Aimo A.","year":"2022","unstructured":"Aimo A.; Castiglione V.; Rapezzi C.; Franzini M.; Panichella G.; Vergaro G.; Gillmore J.; Fontana M.; Passino C.; Emdin M.; RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nat Rev Cardiol  2022,19(10),655-667","journal-title":"Nat Rev Cardiol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","volume":"46","author":"Jiang F.","year":"2017","unstructured":"Jiang F.; Doudna J.A.; CRISPR\u2013Cas9 structures and mechanisms. Annu Rev Biophys  2017,46(1),505-529","journal-title":"Annu Rev Biophys"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/bfgp\/elw025","volume":"16","author":"Torres-Ruiz R.","year":"2017","unstructured":"Torres-Ruiz R.; Rodriguez-Perales S.; CRISPR-Cas9 technology: Applications and human disease modelling. Brief Funct Genomics  2017,16(1),4-12","journal-title":"Brief Funct Genomics"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"eabc9450","DOI":"10.1126\/sciadv.abc9450","volume":"6","author":"Rosenblum D.","year":"2020","unstructured":"Rosenblum D.; Gutkin A.; Kedmi R.; Ramishetti S.; Veiga N.; Jacobi A.M.; Schubert M.S.; Friedmann-Morvinski D.; Cohen Z.R.; Behlke M.A.; Lieberman J.; Peer D.; CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci Adv  2020,6(47),eabc9450","journal-title":"Sci Adv"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jtbi.2014.02.025","volume":"355","author":"Foo J.","year":"2014","unstructured":"Foo J.; Michor F.; Evolution of acquired resistance to anti-cancer therapy. J Theor Biol  2014,355,10-20","journal-title":"J Theor Biol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.oraloncology.2017.02.016","volume":"68","author":"Shaikh M.H.","year":"2017","unstructured":"Shaikh M.H.; Clarke D.T.W.; Johnson N.W.; McMillan N.A.J.; Can gene editing and silencing technologies play a role in the treatment of head and neck cancer? Oral Oncol  2017,68,9-19","journal-title":"Oral Oncol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"625862","DOI":"10.3389\/fmicb.2020.625862","volume":"11","author":"Zhao Y.","year":"2021","unstructured":"Zhao Y.; Wang F.; Wang C.; Zhang X.; Jiang C.; Ding F.; Shen L.; Zhang Q.; Optimization of CRISPR\/Cas system for improving genome editing efficiency in Plasmodium falciparum. Front Microbiol  2021,11,625862","journal-title":"Front Microbiol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.addr.2020.04.010","volume":"168","author":"Song X.","year":"2021","unstructured":"Song X.; Liu C.; Wang N.; Huang H.; He S.; Gong C.; Wei Y.; Delivery of CRISPR\/Cas systems for cancer gene therapy and immunotherapy. Adv Drug Deliv Rev  2021,168,158-180","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jconrel.2022.08.042","volume":"350","author":"Mirjalili Mohanna S.Z.","year":"2022","unstructured":"Mirjalili Mohanna S.Z.; Djaksigulova D.; Hill A.M.; Wagner P.K.; Simpson E.M.; Leavitt B.R.; LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea. J Control Release  2022,350,401-413","journal-title":"J Control Release"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1080\/09205063.2022.2121592","volume":"34","author":"Aziz A.","year":"2023","unstructured":"Aziz A.; Rehman U.; Sheikh A.; Abourehab M.A.S.; Kesharwani P.; Lipid-based nanocarrier mediated CRISPR\/Cas9 delivery for cancer therapy. J Biomater Sci Polym Ed  2023,34(3),398-418","journal-title":"J Biomater Sci Polym Ed"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"820650","DOI":"10.3389\/fcimb.2022.820650","volume":"12","author":"Yu S.","year":"2022","unstructured":"Yu S.; Wang J.; Luo X.; Zheng H.; Wang L.; Yang X.; Wang Y.; Transmission-blocking strategies against malaria parasites during their mosquito stages. Front Cell Infect Microbiol  2022,12,820650","journal-title":"Front Cell Infect Microbiol"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575306957240610102626","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/231211\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575306957240610102626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T13:38:56Z","timestamp":1735479536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/231211\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113895575306957240610102626","relation":{},"ISSN":["1389-5575"],"issn-type":[{"type":"print","value":"1389-5575"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}